Small cell lung cancer: Biological and therapeutic aspects

Critical Reviews in Oncology/Hematology

Volumn 22, Issue 1, 1996, Pages 27-60

  Kristensen, Claus Andrup ^a   Jensen, Peter Buhl ^a,b   Poulsen, Hans Skovgaard ^a,b   Hansen, Heine Høi ^a,b  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ALTRETAMINE; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CARBOPLATIN; CISPLATIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOTOXIN; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 3; LOMUSTINE; METHOTREXATE; MONOCLONAL ANTIBODY; NEUROPEPTIDE; NIMUSTINE; UNINDEXED DRUG; VINCRISTINE; VINDESINE; WARFARIN;

BIOLOGY; CANCER THERAPY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030046011     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(94)00170-7     Document Type: Review

References (373)

1. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035, 1994.
2. Richardson GE, Johnson BE. The biology of lung cancer. Sem Oncol 20:105-127, 1993.
3. Elrington GM, Murray NMF, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychol 54:764-767, 1991.
4. Viglione MP, Creutz CE, Kim YI. Lambert-Eaton syndrome: antigen-antibody interaction and calcium current inhibition in chromaffin cells. Muscle Nerve 15:1325-1333, 1992.
5. Carney DN, Cuttitta F, Moody TW, Minna JD. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 47:821-825, 1987.
6. Moody TW, Cuttitta F. Growth factors and peptide receptors in small cell lung cancer. Life Sci 52:1161-1173, 1993.
7. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 67:37-46, 1993.
8. Damstrup L, Rørth M, Poulsen HS. Growth factors and growth factor receptors in human malignancies, with special reference to human lung cancer: a review. Lung Cancer 5:49-68, 1989.
9. Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res 52:3089-3093, 1992.
10. 1 of human small cell lung cancer cell lines is associated to expression of the type II receptor. Br J Cancer 69:802-808, 1994.
11. 3 in human small cell lung cancer cell lines. Br J Cancer 67:1015-1021, 1993.
12. Sethi T et al. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res 52:2737s-2742s, 1992.
13. Mulshine JL, Treston AM, Brown PH, Birrer MJ, Shaw GL. Initiators and promotors of lung cancer. Chest 103:4s-11s, 1993.
14. Aguayo SM, King TE Jr, Kane MA et al. Urinary levels of bombesin-like peptides in asymptomatic cigarette smokers: a potential risk marker for smoking related diseases. Cancer Res 52:2727s-2731s, 1992.
15. Holst JJ, Hansen M, Bork E, Schwartz TW. Elevated plasma concentrations of C-flanking gastrin-releasing peptide in small cell lung cancer. J Clin Oncol 7:1831-1838, 1989.
16. Woll PJ, Rozengurt E. Multiple neuropeptides mobilise calcium in small cell lung cancer: effects of vasopressin, bradykinin, cholecystokinin, galanin and neurotensin. Biochem Biophys Res Commun 164:66-73, 1989.
17. Kado-Fong H, Malfroy B. Effects of bombesin on human small cell lung cancer cells: evidence for a subset of bombesin non-responsive cell lines. J Cell Biochem 40:431-437, 1989.
18. Bunn PA, Chan D, Dienhart DG, Tolley R, Tagawa M, Jewett PB. Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res 52:24-31, 1992.
19. Minna JD. The molecular biology of lung cancer pathogenesis. Chest 103:449s-456s, 1993.
20. Engelholm SA, Vindeløv LL, Spang-Thomsen M et al. Genetic instability of cell lines derived from a single human small cell carcinoma of the lung. Eur J Cancer Clin Oncol 21:815-824, 1985.
21. Engelholm SA, Spang-Thomsen M, Vindeløv LL et al. Comparison of characteristics of human small cell carcinoma of the lung in patients, in vitro and transplanted into nude mice. Acta Path Microbiol Immunol Scand Sect A 94:325-336, 1986.
22. Vindeøv LL, Hansen HH, Christensen IJ et al. Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res 40:4295-4300, 1980.
23. Carney DN, Gazdar AF, Bunn PA, Guccion JG. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells 1:149-164, 1981.
24. Salvati F, Teodori L, Gagliadi L, Signora M, Aquilini M, Storniello G. DNA flow cytometric studies of 66 human lung tumors analyzed before treatment. Chest 95:1092-1098, 1989.
25. Yokota J, Sugimura T, Terada M. Chromosomal localisation of putative tumor-suppressor genes in several human cancers. Environ Health Perspect 93:121-123, 1991.
26. Rygaard K, Vindeløv LL, Spang-Thomsen M. Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts. Int J Cancer 54:144-152, 1993.
27. Makela TP, Saksela K, Alitalo K. Amplification and rearrangement of L-myc in human small-cell lung cancer. Mutat Res 276:307-315, 1992.
28. Carney DN, Gazdar AF, Bepler G et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45:2913-2923, 1985.
29. Perkins AS, Vande Woude GF. Principles of molecular cell biology of cancer: oncogenes. In: DeVita V Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott, 1993; 35-59.
30. Rowley JD, Mitelman F. Principles of molecular cell biology of cancer: chromosome abnormalities in human cancer and leukemia. In: DeVita V Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott, 1993; 67-91.
31. Hibi K, Takahashi T, Yamakawa K et al. Three distinct regions involved in 3p deletions in human lung cancer. Oncogene 7:445-449, 1992.
32. Daly MC, Xiang RH, Buchhagen D et al. A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. Oncogene 8:1721-1729, 1993.
33. Mori N, Yokota J, Oshimura M et al. Concordant deletions of chromosome 3p and loss of heterozygosity for chromosomes 13 and 17 in small cell lung carcinoma. Cancer Res 49:5130-5135, 1989.
34. Miura I, Graziano SL, Cheng JQ, Doyle LA, Testa JR. Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. Cancer Res 52:1322-1328, 1992.
35. Pietenpol JA, Stein RW, Moran E et al. TGF-beta1 inhibition of c-MYC transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61:777, 1990.
36. Oren M. p53: the ultimate tumor suppressor gene? FASEB J 6:3169-3176, 1992.
37. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253:49-53, 1991.
38. Frebourg T, Friend SH. The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence? J Natl Cancer Inst 85:1554-1557, 1993.
39. Sameshima Y, Matsuno Y, Hirohashi S et al. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene 7:451-457, 1992.
40. Takahashi T, Takahshi T, Suzuki H et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6:1775-1778, 1991.
41. D'Aminco D, Carbone D, Mitsudomi T et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7:339-346, 1992.
42. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075-3079, 1991.
43. Nowell PC. The clonal evolution of tumor cell populations. Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression. Science 194:23-28, 1976.
44. Takahashi T, Carbone D, Takahashi T et al. Wild type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52:2340-2343, 1992.
45. Ookawa K, Shiseki M, Takahashi R, Yoshida Y, Terada M, Yokota J. Reconstitution of the RB gene suppresses the growth of small cell lung carcinoma cells carrying multiple genetic alterations. Oncogene 8:2175-2181, 1993.
46. Sehested M, Hirsch FR, Østerlind K, Olsen JE. Morphologic variations of small cell lung cancer. A histopathologic study of pretreatment and posttreatment specimens in 104 patients. Cancer 57:804-807, 1986.
47. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44:3643-3653, 1984.
48. Borst P. Genetic mechanisms of drug resistance. A review. Rev Oncol 4:87-105, 1991.
49. Weinstein JN, Kohn KW, Grever MR et al. Neural computing in cancer drug development: predicting mechanism of action. Science 258:447-451, 1992.
50. Cole SPC. Multidrug resistance in small cell lung cancer. Cancer J Physiol Pharmacol 70:313-329, 1992.
51. Tsai C, Ihde DC, Kkadyama C, Venzon D, Gazdar AF. Correlation of in vitro drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival. Eur J Cancer 6:1148-1152, 1990.
52. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52:1666-1674, 1992.
53. Jensen PB, Roed H, Sehested M et al. Doxorubicin sensitivity pattern in a panel of small cell lung cancer cell lines: correlation to etoposide and vincristine and inverse correlation to carmustine sensitivity. Cancer Chemother Pharmacol 31:46-52, 1992.
54. Jensen PB, Christensen IJ, Sehested M, Hansen HH, Vindeløv L. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer 67:311-320, 1993.
55. Kristjansen PEG, Hirsch FR. A review of the 5th World Congress on Lung Cancer held by the International Association for the Study of Lung Cancer. Eur Respir J 2:275-279, 1989.
56. Bork E, Ersbøll J, Dombernowsky P, Bergman B, Hansen M, Hansen HH. Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. J Clin Oncol 9:1627-1631, 1991.
57. Hirsch FR, Hansen HH, Hansen M et al. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol 5:585-591, 1987.
58. Ferguson PJ, Fisher MH, Stephenson J, Li D, Zhou B, Cheng Y. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48:5956-5964, 1988.
59. Long BH, Wang L, Lorico A, Wang RCC, Brattain MG, Casazza AM. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51:5275-5284, 1991.
60. Sehested M, Friche E, Jensen PB, Demant EJF. Relationship of VP-16 to the classical multidrug resistance phenotype. Cancer Res 52:2874-2879, 1992.
61. Endicott JA, Ling V. The biochemistry of p-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171, 1989.
62. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861-8869, 1988.
63. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-371, 1989.
64. Reeve JG, Rabbitts PH, Twentyman PR. Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. Br J Cancer 60:339-342, 1989.
65. Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 26:313-317, 1990.
66. de Vries EGE, Meijer C, Timmer-Bosscha H et al. Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res 49:4175-4179, 1989.
67. Jensen PB, Vindeløv L, Roed H et al. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer 60:838-844, 1989.
68. de Jong S, Zijlstra JG, de Vries EGE, Mulder NH. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50:304-309, 1990.
69. Jensen PB, Sørensen BS, Sehested M et al. Different modes of anthracycline interaction with topoisomerase II: separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45:2025-2035, 1993.
70. Cole SPC, Chanda ER, Dicke FP, Gerlach JH, Mirski SEL. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51:3345-3352, 1991.
71. Versantvoort CHM, Broxterman HJ, Pinedo HM et al. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant lung cancer cell lines without P-glycoprotein expression. Cancer Res 52:17-23, 1992.
72. Sehested M, Skovsgaard T, van Deurs B, Winther-Nielsen H. Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br J Cancer 56:747-751, 1987.
73. Demant EJF, Sehested M, Jensen PB. A model for computer simulation of P-glycoprotein and transmembrane delta pH mediated anthracycline transport in multidrug resistant tumor cells. Biochim Biophys Acta 1055:117-125, 1990.
74. Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multi-drug-resistant human lung cancer cell line. Science 258:1650-1654, 1992.
75. Zaman GJR, Versantvoort CHM, Smit JJM et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53:1747-1750, 1993.
76. Frei III E, Holden SA, Gonin R, Waxman DJ, Teicher BA. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemother Pharmacol 33:113-122, 1993.
77. Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67:95-122, 1983.
78. Waud WR, Harrison SD, Gilbert KS, Laster WR Jr, Griswold DP Jr. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Pharmacol 27:456-463, 1991.
79. Frei III E, Cucchi CA, Rosowsky A et al. Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 82:2158-2162, 1985.
80. Porter LL, Johnson DH, Hainswort JD, Hande KR, Greco FA. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 69:479-481, 1985.
81. Nooter K, Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63:663-669, 1991.
82. Pirker R, Walner RJ, Geissler K. et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708-712, 1991.
83. Lai SL, Goldstein LJ, Gottesman MM et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst 81:1144-1145, 1989.
84. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982.
85. Østerlind K. Alternating versus sequential chemothereapy in small cell lung cancer. Lung Cancer 5:173-177, 1989.
86. Hansen HH, Kristjansen PEG. Chemotherapy of small cell lung cancer. Eur J Cancer 27:342-349, 1991.
87. Wu L, Smythe AM, Stinson SF et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 52:3029-3034, 1992.
88. De Vita VT. The influence of information on drug resistance on protocol design. Ann Oncol 2:93-106, 1991.
89. Tvede K et al. Phase II study of topotecan (TC) in patients (pts) with pretreated small-cell lung cancer (SCLC) [abstract]. Proceedings of the 7th World Conference on Lung Cancer, Colorado, June 26th-July 1st, 1994 Lung Cancer 11, Suppl 1: 106, 1994.
90. Masuda N, Fukuoka M, Kusunoki Y et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
91. Cormier Y, Eisenhauer E, Gregg R et al. Gemcitabine: an active new agent in patients (PTS) with previously untreated small cell lung cancer (SCLC). A phase II trial of the NCI Canada Clinical Trials Group (NCIC CTG) (abstract). Proc Am Soc Clin Oncol 12:330, 1993.
92. Sheehan RG, Balaban EP, Cox JV, Frenkel EP. The relative value of conventional staging procedures for developing prognostic models in extensive-stage small-cell lung cancer. J Clin Oncol 8:2047-2053, 1990.
93. Mountain CF. Staging of lung cancer: the new international system. Lung Cancer 3:4-11, 1987.
94. Byhardt RW, Hartz A, Libnoch JA, Hansen R, Cox JD. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys 12:771-777, 1986.
95. Jelinek JS, Redmond III J, Perry JJ et al. Small cell lung cancer: staging with MR imaging. Radiology 177:837-842, 1990.
96. Beiske K, Myklebust AT, Aamdal S, Langholm R, Jakobsen E, Fodstad Y. Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods. Am J Pathol 141:531-538, 1992.
97. Abrams P, Fer M, Faubion C et al. A new procedure for staging small cell lung cancer (SCLC): gamma camera imaging using a technetium-99m labeled monoclonal antibody Fab (abstract). Proc Am Soc Clin Oncol 9:232, 1990.
98. Sagman U, Maki E, Evans WK et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol 9:1639-1649, 1991.
99. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2580 patient Southwest Oncology Group data base. J Clin Oncol 8:1563-1574, 1990.
100. Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 63:986-992, 1991.
101. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 45:2878-2882, 1985.
102. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. Br J Cancer 61:597-604, 1990.
103. Østerlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with or without irradiation. Cancer Res 46:4189-4194, 1986.
104. Maurer LH, Pajak TF. Prognostic factors in small cell carcinoma of the lung: a Cancer and Leukemia Group B study. Cancer Treat Rep 65:767-774, 1981.
105. Fraire AE, Johnson EH, Yesner R, Zhang XB, Spjut HJ, Greenberg SD. Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Hum Pathol 23:520-528, 1992.
106. Goldman RD, Kaplan NO, Hall TC. Lactic dehydrogenase in human neoplastic tissues. Cancer Res 24:389-399, 1964.
107. Cohen MH, Makuch R, Johnston-Early A et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 65:187-195, 1981.
108. Doll DC. Serum lactate dehydrogenase and bone marrow involvement in small-cell carcinoma of the lung. N Engl J Med 312:1262, 1985.
109. Østerlind K, Hirsch F, Pedersen AG. Serum lactate dehydrogenase and bone marrow metastases in small-cell carcinoma of the lung. N Engl J Med 313:759, 1985.
110. Morittu L, Earl HM, Souhami RL et al. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer 59:801-804, 1989.
111. Pflüger K-H, Schmidt L, Merkel M, Jungclas H, Havemann K. Drug monitoring of etoposide (VP 16-213). Correlation of pharmakokinetic parameters to clinical and biochemical data from patients receiving etoposide. Cancer Chemother Pharmacol 20:59-66, 1987.
112. Arbuck SG, Douglass HO, Goodwin P et al. Pharmacokinetics of etoposide (VP) in patients with normal and abnormal liver function (abstract). Proc Am Soc Clin Oncol 4:40, 1985.
113. Sessa C, Rossi C, Zucchetti M et al. Pharmacokinetics of VP16 in patients with impaired renal function (abstract). Proc Am Assoc Cancer Res 26:153, 1985.
114. Herrstedt J, Clementsen P, Hansen OP. Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer. Eur J Cancer 28A:1070-1073, 1992.
115. Jørgensen LGM, Hirsch FR, Skov BG, Østerlind K, Cooper EH, Larsson LI. Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer. Br J Cancer 63:151-153, 1991.
116. Bergh J, Esscher T, Steinholtz L, Nilsson K, Pahlman S. Immunocytochemical demonstration of neuron-specific enolase (NSE) in human lung cancers. Am J Clin Pathol 84:1-7, 1985.
117. Bobrow LG, Hirsch FR, Hay FG et al. An immunohistochemical investigation of diagnostic biopsy material taken from short and long term survivors with small cell lung cancer. Br J Cancer 66:547-551, 1992.
118. Jørgensen LGM, Østerlind K, Hansen HH, Cooper EH. Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC). Br J Cancer 66:594-598, 1992.
119. Harding M, McAllister J, Hulks G et al. Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? Br J Cancer 61:605-607, 1990.
120. Jørgensen LGM, Østerlind K, Hansen HH, Cooper EH. The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer 58:805-807, 1988.
121. Carney DN, Marangos PJ, Ihde DC et al. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 13:583-585, 1982.
122. Akoun GM, Scarna HM, Milleron BJ, Bénichou MP, Herman DP. Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest 87:39-43, 1985.
123. Hansen M, Hansen HH, Hirsch FR et al. Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes. Cancer 45:1432-1437, 1980.
124. Abeloff MD, Trump DL, Baylin SB. Ectopic adrenocorticotropic (ACTH) syndrome and small cell carcinoma of the lung - assessment of clinical implications in patients on combination chemotherapy. Cancer 48:1082-1087, 1981.
125. Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol 10:21-27, 1992.
126. Dimopoulos MA, Fernandez JF, Samaan NA, Holoye PY, Vassilopoulou-Sellin R. Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer 69:66-71, 1992.
127. Stahel RA. Diagnosis, staging, and prognostic factors of small cell lung cancer. Curr Opin Oncol 3:306-311, 1991.
128. Comis RL, Miller M, Ginsberg SJ. Abnormalities in water homeostasis in small cell anaplastic lung cancer. Cancer 45:2414-2421, 1980.
129. Hirsch FR, Matthews MJ, Aisner S et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 62:973-977, 1988.
130. Aisner SC, Finkelstein DM, Ettinger DE, Abeloff MD, Ruckdeschel JC, Eggleston JC. The clinical significance of variant-morphology small-cell carcinoma of the lung. J Clin Oncol 8:402-408, 1990.
131. Fushimi H, Kikui M, Morino H et al. Detection of large cell component in small cell lung carcinoma by combined cytologic and histologic examinations and its clinical implication. Cancer 70:599-605, 1992.
132. Abeloff MD, Ettinger DS, Khouri NF, Lenhard RE Jr. Intensive induction therapy for small cell carcinoma of the lung. Cancer Treat Rep 63:519-524, 1979.
133. Cohen MH, Creaven PJ, Fossieck BE Jr et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:349-354, 1977.
134. Cohen MH, Ihde DC, Bunn PA Jr et al. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 63:163-170, 1979.
135. Hansen HH, Dombernowsky P, Hansen M, Hirsch F. Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. Arch Intern Med 89:177-181, 1978.
136. Hansen HH, Selawry OS, Simon R et al. Combination chemotherapy of advanced lung cancer. A randomized trial. Cancer 38:2201-2207, 1976.
137. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979.
138. Alberto P, Berchtold W, Sonntag R et al. Chemotherapy of small cell carcinoma of the lung: comparison of a cyclic alternative combination with simultaneous combinations of four and seven agents. Eur J Cancer 17:1027-1033, 1981.
139. Natale RB, Shank B, Hilaris BS, Wittes RE. Combination cyclophosphamide, adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer. Am J Med 79:303-308, 1985.
140. Prendiville J, Radford J, Thatcher N et al. Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. J Clin Oncol 9:1446-1452, 1991.
141. Bleehen NM, Girling DJ, Gregor A et al. A Medical Research Council phase II trial of alternating chemotherapy and radiotherapy in small-cell lung cancer. Br J Cancer 64:775-779, 1991.
142. Østerlind K, Sörenson S, Hansen HH et al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 43:6085-6089, 1983.
143. Leary AG, Yang Y-C, Clark SC, Gasson JC, Golde DW, Ogawa M. Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 70:1343-1348, 1987.
144. Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8:230-240, 1990.
145. Østerlind K, Hansen M, Hirsch FR et al. Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens. Ann Oncol 2:41-46, 1991.
146. Havemann K, Wolf M, Holle R et al. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. Cancer 59:1072-1082, 1987.
147. Evans WK., Feld R, Murray N et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Int Med 107:451-458, 1987.
148. Aisner J, Whitacre M, van Echo DA, Wiernik PH. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 66:221-230, 1982.
149. Feld R, Evans WK, Coy P et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 5:1401-1409, 1987.
150. Smith AP, Anderson G, Chappell G, Bowen DR. Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens. Thorax 46:172-174, 1991.
151. Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG. Comparison of cyclophosphamide, doxorubicin, and vincristin with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 9:1438-1445, 1991.
152. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992.
153. Porter LL III, Johnson DH, Hainsworth JD, Hande KR, Greco FA. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 69:479-481, 1985.
154. Lopez JA, Mann J, Grapski RT et al. Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep 69:369-371, 1985.
155. Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 71:941-944, 1987.
156. Hirsch FR, Hansen HH, Hansen M et al. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol 5:585-591, 1987.
157. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, DeBoer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3:1471-1477, 1985.
158. Fukuoka M, Furuse K., Saijo N et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991.
159. Kristjansen PEG, Pedersen AG, Dombernowsky P et al. A three-armed randomized trial in small cell lung cancer (SCLC) of two induction regimens containing teniposide and cisplatin or carboplatin followed by alternating chemotherapy versus alternating chemotherapy only (abstract). Proc Am Soc Clin Oncol 10:252, 1991.
160. Feld R, Evans WK, DeBoer G et al. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol 2:294-304, 1984.
161. Jones AL, Holborn J, Ashley S, Smith IE. Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide. Eur J Cancer 27:866-870, 1991.
162. Anderson H, Prendiville J, Thatcher N, Radford JA, Swindell R. A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. J Cancer Res Clin Oncol 117 (Suppl IV):139-140, 1991.
163. Postmus PE, Splinter TAW, Palmen FMLHG et al. Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. Eur J Cancer 28:96-100, 1992.
164. Giaccone G, Schmidt G, Calciati A. Pilot study of teniposide in combination chemotherapy for small cell lung cancer. Eur J Cancer 27:141-143, 1991.
165. Murray N, Shah A, Osoba D et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9:1632-1638, 1991.
166. Goodman GE, Crowley J, Livingston RB, Rivkin SE, Albain K, McCulloch JH. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. J Clin Oncol 9:453-457, 1991.
167. Miles DW, Earl HM, Souhami RL et al. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol 9:280-285, 1991.
168. Le Chevalier T, Thomas F, Subirana R et al. A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma. Cancer 67:2980-2983, 1991.
169. Loehrer PJ, Rynard S, Ansari R, Songer J, Pennington K, Einhorn L. Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer 69:669-673, 1992.
170. Evans WK, Stewart D, Logan D et al. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer. Semin Oncol 19:51-57, 1992.
171. Gatzemier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L. Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer. J Clin Oncol 10:818-823, 1992.
172. Hosker HSR, McArdle P, Corns PA. Alveolar macrophage function before and during treatment with cytotoxic chemotherapy in patients with small cell lung cancer. Eur J Cancer 27:1711, 1991.
173. Jassem J, Karnicka-Mlodlowska H, Drozd-Lula M et al. Combination
174. Postmus PE, Smit EF, Kirkpatrick A, Splinter TAW. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 29A:204-207, 1993.
175. Saijo N. Combined modality therapy for small cell lung cancer. Oncology 49:2-10, 1992.
176. Abratt RP, Willcox PA, de Groot M, Goodman HT, Jansen ER, Mame Salton DG. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur J Cancer 27:28-30, 1991.
177. Slevin ML, Clark PI, Osborne RJ et al. A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer (abstract). Proc Am Soc Clin Oncol 5:175, 1986.
178. Tummarello D, Isidori P, Pasini F, Cetto G, Cellerino R. Teniposide as single drug therapy for elderly patients affected by small cell lung cancer. Eur J Cancer 28A:1081-1084, 1992.
179. Giaccone G. Teniposide alone and in combination chemotherapy in small cell lung cancer. Semin Oncol 19, No. 2 (Suppl 6):75-80, 1992.
180. Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L. Phase II and III studies with carboplatin in small cell lung cancer. Semin Oncol 19, No. 1 (Suppl 2):28-36, 1992.
181. Bishop JF. Carboplatin/etoposide in small cell lung cancer. Oncology 49 (Suppl 1):11-18, 1992.
182. Gatzemeier U, von Pawel J, Laumen R et al. Carboplatin/etoposide/vincristine therapy in small cell lung cancer. Oncology 49 (Suppl 1):25-33, 1992.
183. Bakker W, Nijhuis-Heddes JMA, van Oosterom AT, Noordijk EM, Hermans J, Dijkman JH. Combined modality treatment of short duration in small cell lung cancer. Eur J Cancer Clin Oncol 20:1033-1037, 1984.
184. Maurer LH, Tulloh M, Weiss RB et al. A randomized combined modality trial in small cell carcinoma of the lung. Comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 45:30-39, 1980.
185. Clamon G, Herndon J, Perry MC et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. J Natl Cancer Inst 85:316-320, 1993.
186. Clarke SJ, Bell DR, Woods RL, Levi JA. Maintenance chemotherapy for small cell carcinoma of the lung: long term follow-up (abstract). Proc Am Soc Clin Oncol 8:248, 1989.
187. Byme MJ, van Hazel G, Trotter J et al. Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. Br J Cancer 60:413-418, 1989.
188. Einhorn L, Greco FA, Cohen H, Birch R. Late consolidation with cisplatin plus VP-16 (PVP 16) following induction chemotherapy with cyclophosphamide, adriamycin and vincristine (CAV) in limited small cell lung cancer (SCLC): a Southeastern Cancer Study Group (SECSG) random prospective study (abstract). Proc Am Soc Clin Oncol 6:166, 1987.
189. Spiro SG, Souhami RL, Geddes DM et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 59:578-583, 1989.
190. Giaccone G, Dalesio O, McVie GJ et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 11:1230-1240, 1993.
191. Blechen NM, Fayers PM, Girling DJ, Stephens RJ. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 59:584-590, 1989.
192. Earl HM, Rudd RM, Spiro SG et al. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 64:566-572, 1991.
193. Lebeau B, Chastang Cl, Allard P, Migueres J, Boita F, Fichet D. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. Eur Respir J 5:286-290, 1992.
194. Splinter TAW. EORTC 08825: induction vs induction plus maintenance chemotherapy (CT) in small cell lung cancer (SCLC). Definitive evaluation (abstract). Proc Am Soc Clin Oncol 7:202, 1988.
195. Murray N. The importance of dose and dose intensity in lung cancer chemotherapy. Semin Oncol 4 (Suppl 4):20-28, 1987.
196. Souhami RL, Harper PG, Linch D et al. High-dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus. Cancer Chemother Pharmacol 10:205-207, 1983.
197. Souhami RL, Finn G, Gregory WM et al. High-dose cyclophosphamide in small-cell carcinoma of the lung. J Clin Oncol 3:958-963, 1985.
198. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307-1317, 1977.
199. Sculier JP, Klastersky J, Stryckmans P, the EORTC Lung Cancer Working Party (Belgium). Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. J Clin Oncol 3:184-191, 1985.
200. Lange A, Kolodziej J, Tomeczko J et al. Aggressive chemotherapy with autologous bone marrow transplantation in small cell lung carcinoma. Arch Immun Ther Exp 39:431-439, 1991.
201. Elias AD, Ayash L, Frei III E et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 85:559-566, 1993.
202. Souhami RL, Hajichristou HT, Miles DW et al. Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. Cancer Chemother Pharmacol 24:321-325, 1989.
203. Banham S, Soukop M, Burnett A et al. Treatment of small cell carcinoma of lung with late dosage intensification programmes containing cyclophosphamide and mesna. Cancer Treat Rev 10:73-77, 1993.
204. Banham S, Burnett A, Stevenson R et al. Pilot study of combination chemotherapy with late dose intensification and autologous marrow rescue in small cell bronchial carcinoma. Br J Cancer 42:486-487, 1982.
205. Klastersky J, Nicaise C, Longeval E, Stryckmans P, the EORTC Lung Cancer Working Party. Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma. Evaluation of efficacy and toxicity and pilot study of a 'late intensification' with autologous bone-marrow rescue. Cancer 50:652-658, 1982.
206. Stewart P, Buckner CD, Thomas ED et al. Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. Cancer Treat Rep 67:1055-1059, 1983.
207. Stahel RA, Takvorian RW, Skarin AT, Canellos GP. Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol 20:1233-1238, 1984.
208. Smith IE, Evans BD, Harland SJ et al. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemother Pharmacol 14:120-124, 1985.
209. Cunningham D, Banham SW, Hutcheon AH et al. High-dose cyclophosphamide and VP-16 as late dosage intensification therapy for small cell carcinoma of the lung. Cancer Chemother Pharmacol 15:303-306, 1985.
210. Spitzer G, Farha P, Valdivieso M et al. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 4:4-13, 1986.
211. Ihde DC, Deisseroth AB, Lichter AS et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 4:1443-1454, 1986.
212. Humblet Y, Symann M, Bosly A et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 5:1864-1873, 1987.
213. Leonard RCF, Duncan LW, Hay FG. Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer. Cancer Res 50:6545-6548, 1990.
214. Kudoh S, Fukuoka M, Negoro S et al. Weekly dose-intensive chemotherapy in patients with small-cell lung cancer: a pilot study. Am J Clin Oncol 15:29-34, 1992.
215. Alba E, Breton JJ, Alonso L, Paredes G, Belon J, Ballesteros P. Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs. Ann Oncol 3:31-35, 1992.
216. Wampler GL, Ahlgren JD, Schulof RS. A pilot study of intensive weekly chemotherapy for extensive disease small-cell lung carcinoma. Cancer Invest 10:97-102, 1992.
217. Ardizzoni A, Venturini M, Crinò L et al. High dose-intensity chemoterapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. Eur J Cancer 29A:687-692, 1993.
218. O'Donnell MR, Ruckdeschel JC, Baxter D, McKneally MF, Caradonna R, Horton J. Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung. Cancer Treat Rep 69:571-575, 1985.
219. Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 3:54-64, 1985.
220. Hande KR, Oldham RK, Fer MF, Richardson RL, Greco FA. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med 73:413-419, 1982.
221. Ihde DC, Mulshine JL, Kramer BS et al. Randomized trial of high versus standard dose etoposide (VP-16) and cisplatin in extensive stage small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 10:240, 1991.
222. Arriagada R, Chevalier TL, Pignon J-P et. al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329:1848-1852, 1993.
223. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 9:499-508, 1991.
224. Andersen M, Kristjansen PEG, Hansen HH. Second-line chemotherapy in small cell lung cancer. Cancer Treat Rev 17:427-436, 1990.
225. Batist G, Carney DN, Cowan KH et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol 4:982-986, 1986.
226. Postmus PE, Berendsen HH, van Zandwijk N et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23:1409-1411, 1987.
227. Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 23:1697-1699, 1987.
228. Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 21:45-48, 1988.
229. Evans WK, Osoba D, Feld R, Shepherd FA, Bazos MJ, DeBoer G. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 3:65-71, 1985.
230. Evans WK, Feld R, Osoba D, Shepherd FA, Dill J, DeBoer G. VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 53:1461-1466, 1984.
231. Sagman U, Lishner M, Maki E et al. Second primary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol 10:1525-1533, 1992.
232. Chiuten DF, Carr DT, Dhingra HM et al. Combination chemotherapy with vindesine and cisplatin for refractory small cell bronchogenic carcinoma. Cancer Treat Rep 70:795-796, 1986.
233. Hino M, Niitani H, Yano T et al. A comparative randomized phase II study of CDDP (C) vs. C with carbazilquinone (CQ) vs. C with etoposide (E) as second-line chemotherapy in small cell lung cancer (SCLC) (abstract). Lung Cancer 4 (Suppl):A115, 1988.
234. Wolff SN, Birch R, Sarma P, Greco FA. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70:583-587, 1986.
235. Cohen MH, Broder LE, Fossieck BE, Bull M, Ihde DC, Minna JD. Combination chemotherapy with vincristine, adriamycin, and procarbazine in previously treated patients with small cell carcinoma. Cancer Treat Rep 61:485-487, 1977.
236. Cantwell BMJ, Bozzino JM, Corns P, Harris AL. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristin (VPAV) for small cell lung cancer. Eur J Cancer Clin Oncol 24:123-129, 1988.
237. Postmus PE, Smit EF, Berendsen HH, Haaxma-Reiche H. Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience. Semin Oncol 19, No. 1 (Suppl 2):17-23, 1992.
238. Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood 63:55-63, 1984.
239. Zacharski LR, Memoli VA, Rousseau SM, Kisiel W. Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung. Cancer 60:2675-2681, 1987.
240. Wojtukiewicz MZ, Zacharski LR, Memoli VA et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 65:481-485, 1990.
241. Zacharski LR, Henderson WG, Rickles FR et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration study no. 75. J Am Med Assoc 245:831-835, 1981.
242. Chahinian AP, Propert KJ, Ware JH et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7:993-1002, 1989.
243. Lebeau B, Chastang Cl, Capron F. Small cell lung cancer: long term results of a randomized trial on aspirin vs. no antiaggregant therapy (abstract). Lung Cancer 7 (Suppl): 129, 1991.
244. Aisner J, Goutsou M, Maurer LH et al. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study. J Clin Oncol 10:1230-1236, 1992.
245. Calvo FA, Hidalgo OF, Gonzalez F et al. Urokinase combination chemotherapy in small cell lung cancer. A phase II study. Cancer 70:2624-2630, 1992.
246. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991.
247. Masuda N, Fukuoka M, Furuse K. CODE chemotherapy with or without recombinant human granulocyte colony stimulating factor in extensive-stage small cell lung cancer. Oncology 49 (Suppl 1):19-24, 1992.
248. Bronchud MH, Scarffe JH, Thatcher N et al. Phase VII study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809-813, 1987.
249. Antman KS, Griffin JD, Elias A et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319: 593-598, 1988.
250. Anderson H, Gurney H, Thatcher N, Swindell R, Scarffe JH, Weiner J. Recombinant human GM-CSF in small cell lung cancer: a phase I/II study. Rec Resul Cancer Res 121: 155-161, 1991.
251. Masuda N, Fukuoka M, Takada M et al. Redevelopment of small-cell lung cancer nine years after the start of therapy. Am J Clin Oncol 14:322-327, 1991.
252. Sagman U, Feld R, Evans WK et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol 9:954-961, 1991.
253. Paccagnella A, Favaretto A, Riccardi A et al. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics. Cancer 72:697-706, 1993.
254. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-493, 1993.
255. Postmus PE, Gietema JA, Damsma O et al. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. J Clin Oncol 10:1131-1140, 1992.
256. Balkwill FR, Smyth JF. Interferons in cancer therapy: a reappraisal. Lancet 2:317-319, 1987.
257. Mattson K, Niiranen A, Pyrhönen S et al. Natural interferon alpha as maintenance therapy for small cell lung cancer. Eur J Cancer 28A:1387-1391, 1992.
258. Kelly K, Bunn PA Jr, Hazuka M, Beasley K, Crowley J, Livingston R. The role of alpha interferon (rINFO2a) maintenance in patients with limited stage SCLC responding to concurrent chemoradiation: a Southwest Oncology Group study (SWOG) (abstract). Proc Am Soc Clin Oncol 12:330, 1993.
259. Mulshine J, Avis I, Carrasquillo J et al. Phase I study of an antigastrin releasing peptide (GRP) monoclonal antibody in patients with lung cancer (abstract). Proc Am Soc Clin Oncol 9:230, 1990.
260. Prevost G, Mormont C, Gunning M, Thomas F. Therapeutic use and perspectives of synthetic peptides in oncology. Acta Oncol 32:209-215, 1993.
261. Anthony L, Johnson D, Hande K et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32:217-223, 1993.
262. Lynch TJ Jr. Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. Chest 103 (Suppl 4):436S-439S, 1993.
263. Petrovich Z, Mietlowski W, Ohanian M, Cox J. Clinical report on the treatment of locally advanced lung cancer. Cancer 40: 72-77, 1977.
264. Medical Research Council Lung Cancer Working Party. Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Br J Cancer 40:1-10, 1979.
265. Deeley TJ. A clinical trial to compare two different tumour dose levels in the treatment of advanced carcinoma of the bronchus. Radiology 17:299-301, 1966.
266. Bergsagel DE, Jenkin RDT, Pringle JF et al. Lung cancer: clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide. Cancer 30:621-627, 1972.
267. Salazar OM, Creech RH. 'The state of the an' toward defining the role of radiation therapy in the management of small cell bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 6:1103-1117, 1980.
268. Arriagada R, Chevalier TL, Baldeyrou P et al. Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease. Int J Rad Oncol Biol Phys 11:1461-1467, 1985.
269. Ihde DC, Bilek FS, Cohen MH, Bunn PA, Eddy J, Minna JD. Response to thoracic radiotherapy in patients with small cell carcinoma of the lung after failure of combination chemotherapy. Radiology 132:443-446, 1979.
270. Souhami RL, Geddes DM, Spiro SG et al. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J Clin Res Ed 288:1643-1646, 1984.
271. Perez CA, Einhom L, Oldham RK et al. Randomized trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol 2:1200-1208, 1984.
272. Østerlind K, Hansen HH, Dombernowski P, Hansen M, Andersen PK. Determinants of complete remission induction and maintenance in chemotherapy with or without irradiation of small cell lung cancer. Cancer Res 47:2733-2736, 1987.
273. Kies MS, Mira J, Crowley JJ et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide field versus reduced field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol 5:592-600, 1987.
274. Johnson DH, Bass D, Einhorn LH et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 11:1223-1229, 1993.
275. Perry MC, Eaton WL, Propert KJ et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316:912-918, 1987.
276. Bunn PA, Lichter AS, Makuch RW et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited small cell lung cancer. Ann Intern Med 106:655, 1987.
277. Pignon J-P, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992.
278. Lau J, Berlin J, Chalmers TC. Meta-analysis of radiotherapy for small-cell lung cancer (letter). N Engl J Med 328:1425-1426, 1993.
279. Murray N, Coy P, Pater J et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11:336-344, 1993.
280. Nielsen OS, Fode K, Bentzen SM et al. Timing of radiotherapy and chemotherapy in limited stage small cell lung cancer (LSCLC). Final analysis (abstract). Eur J Cancer 27 (Suppl 2):S182, 1991.
281. Krarup M, Poulsen HS, Spang-Thomsen M. Cellular radiosensitivity of small cell lung cancer cell lines studied by the ex trapolation method. Int J Radiol Oncol Biol Phys, 1995, in press.
282. Johnson DH, Turrisi AT, Chang AT et al. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 11:879-884, 1993.
283. Turrisi AT 3rd, Glover DJ. Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease. Int J Radiat Oncol Biol Phys 19:1473-1479, 1990.
284. Armstrong JG, Rosenstein MM, Kris MG et al. Twice daily thoracic irradiation for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 21:1269-1274, 1991.
285. Armstrong JG. Long-term outcome of small cell lung cancer. Cancer Treat Rev 17:1-13, 1990.
286. Miller AB, Fow W, Tall R. Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet 2:501-506, 1969.
287. Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 15:278-299, 1988.
288. Shields TW, Higgins GA, Matthews MJ, Keehn MS. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 84:481-488, 1982.
289. Shepherd FA, Ginsberg R, Feld R, Evans WK, Johansen E. Surgical treatment for limited small-cell lung cancer. J Thorac Cardiovasc Surg 101:385-393, 1991.
290. Macchiarini P, Hardin M, Basolo F, Bruno J, Chella A, Angeletti CA. Surgery plus adjuvant chemotherapy for T1-3N0M0 small cell lung cancer. Am J Clin Oncol 14:218-224, 1991.
291. Johnson DH, Einhorn LH, Mandelbaum I, Williams SD, Greco FA. Postchemotherapy resection of residual tumor in limited stage small cell lung cancer. Chest 92:241-246, 1987.
292. Williams CJ, McMillan I, Lea R et al. Surgery after initial chemotherapy for localized small-cell carcinoma of the lung. J Clin Oncol 5:1579-1588, 1987.
293. Shepherd FA, Ginsberg R, Patterson GA et al. Is there ever a role for salvage operations in limited small-cell lung cancer? J Thorac Cardiovasc Surg 101:196-200, 1991.
294. Lad T, Thomas P, Piantadosi S. Surgical resection of small cell lung cancer -a prospective randomized evaluation (abstract). Proc Am Soc Clin Oncol 10:244, 1991.
295. Yamada IC, Saijo N, Kojima A et al. A retrospective analysis of patients receiving surgery after chemotherapy for small cell lung cancer. Jpn J Clin Oncol 21:39-45, 1991.
296. Baker RR, Ettinger DS, Ruckdeschel JD et al.al The role of surgery in the management of selected patients with small-cell carcinoma of the lung. J Clin Oncol 5:697-702, 1987.
297. Zatopek NK, Holoye PY, Holoye PY et al. Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIb). Am J Clin Oncol 14:427-432, 1991.
298. Nugent JL, Bunn PA, Matthews MJ et al. CNS metastases in small cell bronchogenic carcinoma. Increasing frequency and changing pattern with lengthening survival. Cancer 44:1885-1893, 1979.
299. Baglan RJ, Marks JE. Comparison of symptomatic and prophylactic irradiation of brain metastases from oat cell carcinoma of the lung. Cancer 47:41-45, 1981.
300. Felletti R, Souhami RL, Spiro SG et al. Social consequences of brain or liver relapse in small cell carcinoma of the bronchus. Radiother Oncol 4:335-339, 1985.
301. Pedersen AG. Diagnostic procedures in the detection of CNS metastases from small cell lung cancer. In: Hansen HH, ed. Lung Cancer: Basic and Clinical Aspects. Boston: Martinus Nijhoff Publishers, 1986; 153-182.
302. Kristensen CA, Kristjansen PEG, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 10:1498-1502, 1992.
303. Carmichael J, Crane JM, Bunn PA, Glatstein E, Ihde DC. Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 14:455-459, 1988.
304. Green SB, Byar DP, Walker MD et al. Comparison of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67:121-132, 1983.
305. Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA 79:4420-4423, 1982.
306. Crocker EF, Zimmerman RA, Phelps ME, Kuhl DE. The effect of steroids on the extravascular distribution of radiographic contrast material and technetium pertechnetate in brain tumors as determined by computed tomography. Radiology 119:471-474, 1976.
307. Sculier J-P, Feld R, Evans WK et al. Neurologic disorders in patients with small cell lung cancer. Cancer 60:2275-2283, 1987.
308. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:1655-1662, 1987.
309. Shapiro WR, Posner JB, Ushio Y, Chernik NL, Young DF. Treatment of meningeal neoplasms. Cancer Treat Rep 61:733-743, 1977.
310. Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediat Oncol 6:207-213, 1979.
311. Boogerd W, Moffie D, Smets LA. Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis. Cancer 65:452-457, 1990.
312. Ten Hoeve RFA, Twijnstra A. A lethal neurotoxic reaction after intraventricular methotrexate administration. Cancer 62:2111-2113, 1988.
313. Bach F, Agerlin N, Sflrensen JB et al. Metastatic spinal cord compression secondary to lung cancer..J Clin Oncol 10:1781-1787, 1992.
314. Pedersen AG, Bach F, Melgaard B. Frequency, diagnosis, and prognosis of spinal cord compression in small cell bronchogenic carcinoma. A review of 817 consecutive patients. Cancer 55:1818-1822, 1985.
315. Ampil F, Abreo F. Radiotherapeutic palliation of spinal epidural compression in small-cell lung cancer. South Med J 85:266-269, 1992.
316. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. Br J Cancer 61:597-604, 1990.
317. Posner JB. Management of central nervous system metastases. Semin Oncol 4:81-91, 1977.
318. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small-cell and non-small-cell lung cancer. J Clin Oncol 7:607-612, 1989.
319. Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol 10:21-27, 1992.
320. Young RF, Post EM, King GA. Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg 53:741-748, 1980.
321. Sørensen PS, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 30A:22-27, 1994.
322. Aroney RS, Aisner J, Wesley MN et al. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep 67:675-682, 1983.
323. Hansen HH, Dombernowsky P, Hirsch FR, Hansen M, Rygaard J. Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. Cancer 46:279-284, 1980.
324. Cox JD, Petrovich Z, Paig C, Stanley K. Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung. Preliminary report of a cooperative trial. Cancer 42:1135-1140, 1978.
325. Perez CA, Einhorn L, Oldham RK et al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol 2:1200-1208, 1984.
326. Licciardello JTW, Cersosimo RJ, Karp DD, Hoffer SM, Paquette-Tello DA, Ki Hong W. Disturbing central nervous system complications following combination chemotherapy and prophylactic whole-brain irradiation in patients with small cell lung cancer. Cancer Treat Rep 69:1429-1430, 1985.
327. Graus F, Elkon KB, Cordon-Cardo C, Posner JB. Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med 80:45-52, 1986.
328. Pedersen AG, Bishop JF, Bleehen NM et al. Management of CNS metastases in small cell lung cancer: a consensus report. Lung Cancer 5:140-142, 1989.
329. Kristjansen PEG, Kristensen CA. The role of prophylactic cranial irradiation in the management of small cell lung cancer. Cancer Treat Rev 19:3-16, 1993.
330. Cullen M. The design of phase II trials. Lung Cancer 5:214-220, 1990.
331. Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis EA. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol 10:484-498, 1992.
332. Monks A, Scudiero D, Skehan P et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766, 1991.
333. Daniels JR, Chak LY, Sikic BI et al. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 2:1192-1199, 1984.
334. Østerlind K, Pedersen AG, Vindeløv L et al. Alternating or continuous chemotherapy of extensive stage small cell lung cancer (SCC). Results of a controlled trial on 204 patients (abstract). Lung Cancer 2:127-128, 1986.
335. Pedersen AG, Østerlind K, Vindeløv L et al. Alternating or continuous chemotherapy of small cell lung cancer (SCC). A 3 armed randomized trial (abstract). Proc Am Soc Clin Oncol 6:185, 1987.
336. Goodman GE, Crowley JJ, Blasko JC et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group study. J Clin Oncol 8:39-47, 1990.
337. Wolf M, Pritsch M, Drings P et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. J Clin Oncol 9:614-624, 1991.
338. Banham SW, Henderson AF, Bicknell S, Hughes J, Milroy R, Monie RD. High dose epirubicin chemotherapy in untreated poorer prognosis small cell lung cancer. Respir Med 84:241-244, 1990.
339. Rosenthal M, Kefford R, Raghavan D, Stuart-Harris R. Epirubicin: a phase II study in recurrent small-cell lung cancer. Cancer Chemother Pharmacol 28:220-222, 1991.
340. Rigas JR, Kris MG, Gralla RJ, Heelan RT, Marks LD. Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer. Invest N Drugs 9:187-190, 1993.
341. Pallares C, Izquierdo MA, Paredes A, Sagarra AF, Andrés LD, López JJL. A phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer. Cancer 68:40-43, 1991.
342. Kleisbauer JP, Vergeret J, Balmes P et al. Phase II study of pirarubicin in untreated metastatic small cell lung carcinoma. Eur J Cancer 27:943, 1991.
343. Shepherd FA, MacCormick R, Eisenhauer EA. Phase II study of sulofenur (LY 186641) in untreated patients with extensive small cell lung cancer. Ann Oncol 2:772-773, 1991.
344. Macaulay VM, Smith IE, Everard MJ, Teale JD, Reubi J-C, Millar JL. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer 64:451-456, 1991.
345. Maroun J, Ruckdeschel J, Natale R et al. A phase II study of brequinar sodium (DuP 785, NSC 368390) in lung cancers (ca) (abstract). Proc Am Soc Clin Oncol 10:259, 1991.
346. Jensen PB, Larsen SK, Stilbo I. Phase II study of high-dose aclarubicin in previously treated patients with small cell lung cancer. Cancer Chemother Pharmacol 30:219-220, 1992.
347. Planting ASTh, Splinter TAW, Ardizzoni A et al. Phase II study of ACNU as second-line treatment in small cell lung cancer. Cancer Chemother Pharmacol 29:409-411, 1992.
348. Quoix EA, Giaccone G, Jassem J et al. Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Group. Eur J Cancer 28A:1667-1670, 1992.
349. Wiesenfeld M, Su J, Jett J. Phase II study of edatrexate (10-EDAM) in patients with small cell carcinoma (SCC) of the lung (abstract). Proc Am Soc Clin Oncol 11:311, 1992.
350. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C et al. EORTC phase II study of navelbine (NVB) in previously treated patients (pts) with small cell lung carcinoma (SCLC) (abstract). Proc Am Soc Clin Oncol 11:309, 1992.
351. Sklarin NT, Wiernik PH, Grove WR et al. A phase II trial of CI-921 in advanced malignancies. Invest N Drugs 10:309-312, 1992.
352. Baselga J, Kris MG, Scher HI, Phillips M, Heelan RT. Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer. Invest N Drugs 11:85-86, 1993.
353. Williamson SK, Crowley J, Livingston RB, Weiss G. Phase II trial of 6-thioguanine administered as 120 h continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study. Invest N Drugs 11:81-83, 1993.
354. Smyth JF, Bowman A, Smith I, Sessa C, Kaye S. Taxotere is active in small cell lung cancer (SCLC). A phase II trial of the EORTC Early Clinical Trials Group (ECTG) (abstract). Proceedings of the European Congress on Clinical Oncology and Cancer Nursing (ECCO) S154, 1993.
355. Ettinger DS, Finkelstein DM, Sarma R, Johnson DH. Phase II study of taxol in patients with extensive-stage small cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (abstract). Proc Am Soc Clin Oncol 12:329, 1993.
356. Cullen M, Morgan D, Gregory W et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol 17:157-160, 1986.
357. Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993.
358. Hamm JT, Schiller JH, Oken MM, Gallmeier WM, Rusthoven J, Israel RJ. Granulocyte-macrophage colony stimulating factor (GM-CSF) in small cell carcinoma of the lung (SCCL): preliminary analysis of a randomized controlled trial (abstract). Proc Am Soc Clin Oncol 10:255, 1991.
359. Fox RM, Woods RL, Brodie GN, Tattersall MHN. A randomized study: small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 6:1083-1087, 1980.
360. Lebeau B, Chastang C, Brechot JM, Capron F. A randomized trial of delayed thoracic radiotherapy in complete responder patients with small-cell lung cancer. Chest 104:726-733, 1993.
361. Carlson RW, Sikic BI, Gandara DR et al. Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. Cancer 68:948-958, 1991.
362. Lennox SC, Flavell G, Pollock DJ, Thomsen V, Wilkins JL. Results of resection for oat-cell carcinoma of the lung. Lancet 2.11:925-927, 1968.
363. Fox W, Scadding JD. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Lancet 14.7:63-65, 1973.
364. Shore DF, Paneth M. Survival after resection of small cell carcinoma of the bronchus. Thorax 35:819-822, 1980.
365. Matthews MJ, Rosencweig M, Staquet MJ, Minna JD, Muggia FM. Long-term survivors with small cell carcinoma of the lung. Eur J Cancer 16:527-531, 1979.
366. Jackson DV Jr, Richards F II, Cooper MR et al. Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study. J Am Med Assoc 237:2730-2733, 1977.
367. Beiler DD, Kane RC, Bernath AM, Cashdollar MR. Low dose elective brain irradiation in small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 5:941-945, 1979.
368. Maurer LH, Tulloh M, Weiss RB et al. A randomized combined modality trial in small cell carcinoma of the lung. Comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 45:30-39, 1980.
369. Eagan RT, Frytak S, Lee RE, Creagan ET, Ingle JN, Nichols WC. A case for preplanned thoracic and prophylactic whole brain radiation therapy in !united small-cell lung cancer. Cancer Clin Trials 4:261-266, 1981.
370. Katsenis AT, Karpasitis N, Giannakakis D, Maragoudakis N, Kiparissiadis P. Elective brain irradiation in patients with small-cell carcinoma of the lung: preliminary report. Lung Cancer, International Congress Series 558, Excerpta Medica 277-284, 1982.
371. Seydel HG, Creech R, Pagano M et al. Prophylactic versus no brain irradiation in regional small cell lung carcinoma. Am J Clin Oncol 8:218-223, 1985.
372. Niiranen A, Holsti P, Salmo M. Treatment of small cell lung cancer. Two-drug versus four-drug chemotherapy and locoregional irradiation with or without prophylactic cranial irradiation. Acta Oncol 28:501-505, 1989.
373. Ohonoshi T, Ueoka H, Kawahara S et al. Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result. Lung Cancer 10:47-54, 1993.